COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS

Abstract

Annually, all over the world there are 300 000 new patients with leukemia (approximately 3% of all oncology diseases), and mortality due to leukemia is 220 000 patients. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We performed cost-effectiveness analysis on the basis of two tyrosine kinase inhibitors in Russian Federation – nilotinib (Tasigna) and imatinib (Gleevec) in CML in the chronic phase (CP) treatment as firstline therapy. Treatment with Tasigna compared with Gleevec characterizes as dominant according to used 1-year time horizons.

Keywords

• pharmacoeconomic analysis
• chronic myeloid leukemia
• nilotinib
• tasigna
• imatinib
• gleevec
• cost-effectiveness analysis
• cost-utility analysis
• health technology assessment
• first-line treatment
• tyrosine-kinase inhibitors